Breaking News Instant updates and real-time market news.

14:15
01/08/21
01/08
14:15
01/08/21
14:15

Action Economics Survey results

Action Economics Survey results: a decline in nonfarm payroll was the risk, and the December jobs report obliged. But, most of the weakness was registered in the leisure/hospitality sector as bars and restaurants took a big hit from the recent shutdowns and social distancing requirements. The overall report was not as poor as the headline contraction suggested however. And equity markets have been looking ahead with optimism over vaccines and on the potential for a heavy dose or two of fiscal stimulus under the new Biden administration, overshadowing the threat of higher taxes and increased regulations. Treasuries, meanwhile, are sensing rising inflation dynamics. There is more key data due out next week that is expected to reflect some of the slowing in growth into year end amid the surge in virus cases and restrictions, as well as more signs of rising price pressures. The Survey Medians show retail sales rebounding a modest 0.2% in December, with the ex-auto component slipping -0.1%. However, industrial production is projected increasing 0.5%, while the Empire State manufacturing index improving to 5.6 in January. Also, both headline CPI and PPI are seen popping 0.4% with the core rates edging up 0.2%, respectively, in December.

TODAY'S FREE FLY STORIES

Initiation
Churchill Downs initiated with an Outperform at Macquarie » 20:59
06/17/21
06/17
20:59
06/17/21
20:59
CHDN

Churchill Downs

$192.01 /

-4.55 (-2.31%)

Macquarie analyst Jordan…

Macquarie analyst Jordan Bender initiated coverage of Churchill Downs with an Outperform rating and $254 price target.

ShowHide Related Items >><<
CHDN Churchill Downs
$192.01 /

-4.55 (-2.31%)

CHDN Churchill Downs
$192.01 /

-4.55 (-2.31%)

05/14/21
Fly Intel: Top five analyst upgrades
05/14/21 Jefferies
Jefferies upgrades Churchill Downs to Buy after recent weakness
05/14/21 Jefferies
Churchill Downs upgraded to Buy from Hold at Jefferies
04/27/21 Truist
Red Rock Resorts price target raised to $42 from $34 at Truist
CHDN Churchill Downs
$192.01 /

-4.55 (-2.31%)

CHDN Churchill Downs
$192.01 /

-4.55 (-2.31%)

CHDN Churchill Downs
$192.01 /

-4.55 (-2.31%)

Hot Stocks
Cathie Wood's ARK Investment bought 149K shares of Blade Air Mobility today  20:52
06/17/21
06/17
20:52
06/17/21
20:52
BLDE

Blade Air Mobility

$11.43 /

+0.2 (+1.78%)

 
ShowHide Related Items >><<
BLDE Blade Air Mobility
$11.43 /

+0.2 (+1.78%)

BLDE Blade Air Mobility
$11.43 /

+0.2 (+1.78%)

06/03/21
Fly Intel: Top five analyst initiations
06/03/21 Citi
Blade Air Mobility initiated with a Buy at Citi
BLDE Blade Air Mobility
$11.43 /

+0.2 (+1.78%)

BLDE Blade Air Mobility
$11.43 /

+0.2 (+1.78%)

Hot Stocks
Cathie Wood's ARK Investment bought 23K shares of Kratos Defense on Thursday  20:51
06/17/21
06/17
20:51
06/17/21
20:51
KTOS

Kratos Defense

$26.51 /

+0.27 (+1.03%)

 
ShowHide Related Items >><<
KTOS Kratos Defense
$26.51 /

+0.27 (+1.03%)

KTOS Kratos Defense
$26.51 /

+0.27 (+1.03%)

05/06/21 Noble Capital
Kratos Defense upgraded to Outperform from Market Perform at Noble Capital
03/01/21 Alembic Global
Kratos Defense downgraded to Neutral from Overweight at Alembic Global
02/26/21 Noble Capital
Kratos Defense downgraded to Market Perform from Outperform at Noble Capital
02/18/21
Fly Intel: Top five analyst downgrades
KTOS Kratos Defense
$26.51 /

+0.27 (+1.03%)

  • 19
    Jun
KTOS Kratos Defense
$26.51 /

+0.27 (+1.03%)

KTOS Kratos Defense
$26.51 /

+0.27 (+1.03%)

Upgrade
Arco Platform upgraded to Outperform from Market Perform at Itau BBA » 20:49
06/17/21
06/17
20:49
06/17/21
20:49
ARCE

Arco Platform

$32.26 /

-0.01 (-0.03%)

Itau BBA analyst Gustavo…

Itau BBA analyst Gustavo Miele upgraded Arco Platform to Outperform from Market Perform with a price target of $47, down from $57.

ShowHide Related Items >><<
ARCE Arco Platform
$32.26 /

-0.01 (-0.03%)

ARCE Arco Platform
$32.26 /

-0.01 (-0.03%)

05/11/21 BofA
Vasta Platform downgraded to Neutral from Buy at BofA
05/06/21 Morgan Stanley
Arco Platform upgraded to Overweight on valuation at Morgan Stanley
05/06/21 Morgan Stanley
Arco Platform upgraded to Overweight from Equal Weight at Morgan Stanley
09/02/20 UBS
Arco Platform upgraded to Buy from Neutral at UBS
ARCE Arco Platform
$32.26 /

-0.01 (-0.03%)

  • 09
    Sep
ARCE Arco Platform
$32.26 /

-0.01 (-0.03%)

Downgrade
New Oriental Education downgraded to Hold from Buy at HSBC » 20:21
06/17/21
06/17
20:21
06/17/21
20:21
EDU

New Oriental Education

$7.62 /

-0.745 (-8.91%)

HSBC analyst Charlotte…

HSBC analyst Charlotte Wei downgraded New Oriental Education to Hold from Buy with price target of HK$71.76.

ShowHide Related Items >><<
EDU New Oriental Education
$7.62 /

-0.745 (-8.91%)

EDU New Oriental Education
$7.62 /

-0.745 (-8.91%)

06/16/21 Morgan Stanley
TAL Education cut to Underweight on K9-related business risk at Morgan Stanley
06/16/21 Morgan Stanley
New Oriental Education downgraded on K9-related business risk at Morgan Stanley
06/16/21 Morgan Stanley
New Oriental Education downgraded to Equal Weight from Overweight at Morgan Stanley
06/07/21 Credit Suisse
New Oriental Education downgraded to Neutral from Outperform at Credit Suisse
EDU New Oriental Education
$7.62 /

-0.745 (-8.91%)

EDU New Oriental Education
$7.62 /

-0.745 (-8.91%)

EDU New Oriental Education
$7.62 /

-0.745 (-8.91%)

EDU New Oriental Education
$7.62 /

-0.745 (-8.91%)

Hot Stocks
Innovent Biologics doses first patient in phase 2 tiral of Taletrectinib » 20:19
06/17/21
06/17
20:19
06/17/21
20:19
IVBXF

Innovent Biologics

$11.45 /

+ (+0.00%)

Innovent Biologics…

Innovent Biologics announced that the first patient has been dosed in a Phase II basket trial of taletrectinib for solid tumors containing NTRK fusion. In June 2021, Innovent entered an exclusive agreement with AnHeart Therapeutics Co., Ltd., a clinical stage oncology company focused on underserved patients in global markets, under which Innovent obtained exclusive rights to co-develop and commercialize taletrectinib in Greater China.

ShowHide Related Items >><<
IVBXF Innovent Biologics
$11.45 /

+ (+0.00%)

IVBXF Innovent Biologics
$11.45 /

+ (+0.00%)

11/03/20 Daiwa
Innovent Biologics initiated with a Buy at Daiwa
07/08/20 JPMorgan
Innovent Biologics downgraded to Neutral from Overweight at JPMorgan
Hot Stocks
Medifast CEO sells 13.5K shares of common stock » 19:47
06/17/21
06/17
19:47
06/17/21
19:47
MED

Medifast

$268.81 /

-4.63 (-1.69%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MED Medifast
$268.81 /

-4.63 (-1.69%)

MED Medifast
$268.81 /

-4.63 (-1.69%)

05/05/21 B. Riley
Medifast price target raised to $400 from $310 at B. Riley
05/05/21 DA Davidson
Medifast price target raised to $395 from $302 at DA Davidson
02/26/21 B. Riley
Medifast price target raised to $310 from $300 at B. Riley Securities
02/19/21 B. Riley
Medifast price target raised to $300 from $250 at B. Riley Securities
MED Medifast
$268.81 /

-4.63 (-1.69%)

MED Medifast
$268.81 /

-4.63 (-1.69%)

Hot Stocks
Pennant Group CEO sells 70K shares of common stock » 19:46
06/17/21
06/17
19:46
06/17/21
19:46
PNTG

Pennant Group

$43.64 /

+2.64 (+6.44%)

In a regulatory filing,…

In a regulatory filing, Pennant Group disclosed that its CEO Daniel Walker sold 70K shares of common stock on June 15th in a total transaction size of $2.84M, reducing his stake by about 4%.

ShowHide Related Items >><<
PNTG Pennant Group
$43.64 /

+2.64 (+6.44%)

PNTG Pennant Group
$43.64 /

+2.64 (+6.44%)

06/10/21 RBC Capital
RBC Capital upgrades Pennant Group to Outperform on improving demand environment
06/10/21 RBC Capital
Pennant Group upgraded to Outperform from Sector Perform at RBC Capital
01/05/21 Truist
The Pennant Group price target raised to $60 from $44 at Truist
11/12/20 RBC Capital
The Pennant Group price target raised to $44 from $40 at RBC Capital
PNTG Pennant Group
$43.64 /

+2.64 (+6.44%)

PNTG Pennant Group
$43.64 /

+2.64 (+6.44%)

Hot Stocks
CAI International to be acquired by Mitsubishi HC Capital at $56 per share » 19:35
06/17/21
06/17
19:35
06/17/21
19:35
CAI

CAI International

$38.19 /

-1.97 (-4.91%)

CAI International…

CAI International announced that it has entered into a definitive agreement to be acquired by Mitsubishi HC Capital Inc. . Under the terms of the merger agreement with MHC, MHC will acquire all of CAI's outstanding and fully diluted common stock in an all-cash transaction for $56.00 per share, which represents a total equity value of approximately $1.1B, consisting of $104M of preferred stock and $986M of common stock equity value, assuming a fully-diluted share count of 17.6 million based on the treasury stock method, and an enterprise value of $2.9B, based on balance sheet information included in the Company's most recent Quarterly Report on Form 10-Q as of March 31, 2021. Chairman David Remington says: "After a review of strategic alternatives by our Board of Directors, we are pleased to reach this agreement with MHC, which we believe is in the long-term best interests of our shareholders. This merger is the culmination of discussions that started in Fall of 2019. During those discussions we have been most impressed by the vision of MHC, a vision shared by Hiromitsu Ogawa, who founded CAI over 30 years ago. Mr. Ogawa built a world class container leasing company by focusing on delivering value to customers and we are pleased that this vision will endure. We believe our shipping line customers and manufacturing partners will most certainly benefit from the scale and financial strength of the merged company."

ShowHide Related Items >><<
CAI CAI International
$38.19 /

-1.97 (-4.91%)

CAI CAI International
$38.19 /

-1.97 (-4.91%)

06/09/21 B. Riley
CAI International transferred with Buy at B. Riley
03/26/21 B. Riley
CAI International price target raised to $60 from $50 at B. Riley Securities
02/17/21 B. Riley
CAI International price target raised to $50 from $44 at B. Riley Securities
01/19/21 B. Riley
Triton, Textainer, CAI boosted by 'containergeddon,' says B. Riley Securities
CAI CAI International
$38.19 /

-1.97 (-4.91%)

CAI CAI International
$38.19 /

-1.97 (-4.91%)

Syndicate
Hutchison China MediTech launches Hong Kong IPO of 104M shares » 19:34
06/17/21
06/17
19:34
06/17/21
19:34
HCM

Hutchison China MediTech

$28.28 /

+0.04 (+0.14%)

HUTCHMED announces the…

HUTCHMED announces the launch of its Hong Kong public offerin, which forms part of the global offering of 104M new ordinary shares and the proposed primary listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code "13". The Company will receive all of the net proceeds from the Global Offering. The Global Offering initially comprises 13M new Shares under the Hong Kong Public Offering and 91M new Shares under the international offering, representing approximately 12.5% and 87.5% of the total number of Offer Shares in the Offering, respectively, subject to re-allocation between the Hong Kong Public Offering and the International Offering for any over-subscriptions in the Hong Kong Public Offering and over-allotment. In addition, the Company expects to grant the international underwriters an over-allotment option to purchase up to an additional 15.6M new Shares in the International Offering, representing not more than 15% of the Offer Shares initially available under the Global Offering. The offer price for the Global Offering will be not more than HK$45.00 per Share, which is equivalent to approximately $29 per American depositary share or GBP 4.15 per Share.

ShowHide Related Items >><<
HCM Hutchison China MediTech
$28.28 /

+0.04 (+0.14%)

HCM Hutchison China MediTech
$28.28 /

+0.04 (+0.14%)

10/02/20 Deutsche Bank
Hutchison China MediTech initiated with a Buy at Deutsche Bank
HCM Hutchison China MediTech
$28.28 /

+0.04 (+0.14%)

HCM Hutchison China MediTech
$28.28 /

+0.04 (+0.14%)

Recommendations
Arthur J. Gallagher price target raised to $159 from $148 at Keefe Bruyette » 19:23
06/17/21
06/17
19:23
06/17/21
19:23
AJG

Arthur J. Gallagher

$139.40 /

-2.315 (-1.63%)

, WLTW

Willis Towers Watson

$232.10 /

-5.12 (-2.16%)

Keefe Bruyette analyst…

Keefe Bruyette analyst Meyer Shields raised the firm's price target on Arthur J. Gallagher (AJG) to $159 from $148 and keeps an Outperform rating on the shares following the company's investor meeting. Management was upbeat about sustained property and casualty rate increases, improving economic prospects and eventual prospects for closing on the Willis Towers Watson (WLTW) assets, which remains the likeliest outcome despite the Department of Justice's lawsuit, Shields tells investors in a research note.

ShowHide Related Items >><<
WLTW Willis Towers Watson
$232.10 /

-5.12 (-2.16%)

AJG Arthur J. Gallagher
$139.40 /

-2.315 (-1.63%)

AJG Arthur J. Gallagher
$139.40 /

-2.315 (-1.63%)

05/21/21
Fly Intel: Top five analyst initiations
05/21/21 BofA
Arthur J. Gallagher initiated with an Underperform at BofA
05/18/21 Deutsche Bank
Arthur J. Gallagher price target raised to $160 from $145 at Deutsche Bank
05/03/21 Raymond James
Arthur J. Gallagher price target raised to $165 from $155 at Raymond James
WLTW Willis Towers Watson
$232.10 /

-5.12 (-2.16%)

06/17/21 William Blair
Aon valuation limits downside after DOJ suit, says William Blair
06/17/21 Citi
Citi surprised by DOJ lawsuit to block Aon, Willis deal
05/04/21 Deutsche Bank
Willis Towers Watson price target raised to $265 from $221 at Deutsche Bank
05/03/21 JPMorgan
Aon plc price target raised to $249 from $241 at JPMorgan
WLTW Willis Towers Watson
$232.10 /

-5.12 (-2.16%)

AJG Arthur J. Gallagher
$139.40 /

-2.315 (-1.63%)

  • 13
    May
WLTW Willis Towers Watson
$232.10 /

-5.12 (-2.16%)

AJG Arthur J. Gallagher
$139.40 /

-2.315 (-1.63%)

WLTW Willis Towers Watson
$232.10 /

-5.12 (-2.16%)

Initiation
CI Financial initiated with an Outperform at Keefe Bruyette » 19:21
06/17/21
06/17
19:21
06/17/21
19:21
CIXX

CI Financial

$17.61 /

-0.19 (-1.07%)

Keefe Bruyette analyst…

Keefe Bruyette analyst Robert Lee initiated coverage of CI Financial with an Outperform rating and C$28 price target. The analyst says the company is transforming into a North America wealth manager via U.S. acquisitions.

ShowHide Related Items >><<
CIXX CI Financial
$17.61 /

-0.19 (-1.07%)

CIXX CI Financial
$17.61 /

-0.19 (-1.07%)

05/14/21 Canaccord
CI Financial price target raised to C$27.50 from C$26.50 at Canaccord
05/14/21 BMO Capital
CI Financial price target raised to C$26 from C$23 at BMO Capital
05/14/21 CIBC
CI Financial price target raised to C$23 from C$21 at CIBC
05/14/21 RBC Capital
CI Financial price target raised to C$25 from C$24 at RBC Capital
CIXX CI Financial
$17.61 /

-0.19 (-1.07%)

Syndicate
Cyteir Therapeutics 7.4M share IPO priced at $18.00 » 19:21
06/17/21
06/17
19:21
06/17/21
19:21
CYT

Cyteir Therapeutics

/

+

The deal priced at high…

The deal priced at high end of $16.00-$18.00 range. JPMorgan, Morgan Stanley and BofA are acting as joint book running managers for the offering.

ShowHide Related Items >><<
  • 18
    Jun
Downgrade
Coles Group downgraded to Neutral from Buy at Citi » 19:10
06/17/21
06/17
19:10
06/17/21
19:10
CLEGF

Coles Group

$13.00 /

+ (+0.00%)

Citi analyst Bryan…

Citi analyst Bryan Raymond downgraded Coles Group to Neutral from Buy with a A$17.20 price target.

ShowHide Related Items >><<
CLEGF Coles Group
$13.00 /

+ (+0.00%)

04/30/21 Citi
Coles Group upgraded to Buy from Neutral at Citi
04/29/21 Credit Suisse
Coles Group upgraded to Outperform from Neutral at Credit Suisse
10/05/20 Credit Suisse
Coles Group upgraded to Outperform from Neutral at Credit Suisse
Periodicals
eBay set to sell South Korea business for $3.1B, FT reports » 19:10
06/17/21
06/17
19:10
06/17/21
19:10
EBAY

eBay

$65.33 /

-0.75 (-1.13%)

, SFTBY

SoftBank

$36.10 /

-0.05 (-0.14%)

, CPNG

Coupang

$39.78 /

+1.1 (+2.84%)

eBay (EBAY) is slated to…

eBay (EBAY) is slated to sell its South Korea arm to a local consortium for $3.1B as rivals aim to turn up the heat on SoftBank-backed (SFTBY) Coupang (CPNG) in the market, the Financial Times' Song Jung-a reports, citing people with knowledge of the matter. The consortium, which includes South Korea's largest brick-and-mortal retailer E-Mart and internet company Naver, intends to purchase an 80% interest in eBay Korea for about $3.1B, with eBay keeping the remaining 20%, the author says. The deal could help the consortium overtake Coupang, which raised $4.6B in an IPO in New York in March, the author notes. Reference Link

ShowHide Related Items >><<
SFTBY SoftBank
$36.10 /

-0.05 (-0.14%)

EBAY eBay
$65.33 /

-0.75 (-1.13%)

CPNG Coupang
$39.78 /

+1.1 (+2.84%)

EBAY eBay
$65.33 /

-0.75 (-1.13%)

06/16/21 Baird
eBay volume appears to be tracking in-line, says Baird
05/03/21 BMO Capital
eBay price target lowered to $63 from $67 at BMO Capital
04/29/21
Fly Intel: Top five analyst downgrades
04/29/21 Wedbush
eBay downgraded to Neutral at Wedbush on lower visibility into post-COVID GMV
SFTBY SoftBank
$36.10 /

-0.05 (-0.14%)

06/08/21 Jefferies
SoftBank upgraded to Buy from Hold at Jefferies
04/20/21 Citi
Nvidia deal for Arm has only 10% chance of closing, says Citi
03/11/21 Jefferies
SoftBank downgraded to Hold from Buy at Jefferies
03/10/21 Morgan Stanley
SoftBank resumed with an Equal Weight at Morgan Stanley
CPNG Coupang
$39.78 /

+1.1 (+2.84%)

05/13/21 Deutsche Bank
Deutsche Bank upgrades Coupang to Buy with 30% potential upside
05/13/21 Mizuho
Coupang price target lowered to $40 from $50 at Mizuho
05/13/21 Citi
Coupang price target lowered to $39 from $50 at Citi
05/13/21 Deutsche Bank
Coupang upgraded to Buy from Hold at Deutsche Bank
EBAY eBay
$65.33 /

-0.75 (-1.13%)

CPNG Coupang
$39.78 /

+1.1 (+2.84%)

  • 11
    Mar
SFTBY SoftBank
$36.10 /

-0.05 (-0.14%)

EBAY eBay
$65.33 /

-0.75 (-1.13%)

CPNG Coupang
$39.78 /

+1.1 (+2.84%)

SFTBY SoftBank
$36.10 /

-0.05 (-0.14%)

EBAY eBay
$65.33 /

-0.75 (-1.13%)

CPNG Coupang
$39.78 /

+1.1 (+2.84%)

EBAY eBay
$65.33 /

-0.75 (-1.13%)

CPNG Coupang
$39.78 /

+1.1 (+2.84%)

Hot Stocks
Applied Materials CEO sells 102.9K shares of common stock » 19:06
06/17/21
06/17
19:06
06/17/21
19:06
AMAT

Applied Materials

$137.28 /

+0.32 (+0.23%)

In a regulatory filing,…

In a regulatory filing, Applied Materials disclosed that its CEO Gary Dickerson sold 102.9K shares of common stock on June 15th in a total transaction size of $14.4M, reducing his stake by about 5%.

ShowHide Related Items >><<
AMAT Applied Materials
$137.28 /

+0.32 (+0.23%)

AMAT Applied Materials
$137.28 /

+0.32 (+0.23%)

05/21/21 Susquehanna
Applied Materials price target raised to $170 from $155 at Susquehanna
05/21/21 JPMorgan
Applied Materials price target raised to $160 from $146 at JPMorgan
05/21/21 Mizuho
Applied Materials price target raised to $158 from $155 at Mizuho
05/17/21 Morgan Stanley
Applied Materials price target raised to $137 from $113 at Morgan Stanley
AMAT Applied Materials
$137.28 /

+0.32 (+0.23%)

AMAT Applied Materials
$137.28 /

+0.32 (+0.23%)

AMAT Applied Materials
$137.28 /

+0.32 (+0.23%)

AMAT Applied Materials
$137.28 /

+0.32 (+0.23%)

Hot Stocks
PDS Biotechnology CFO buys 17.6K shares of common stock » 19:04
06/17/21
06/17
19:04
06/17/21
19:04
PDSB

PDS Biotechnology

$10.00 /

+0.655 (+7.01%)

In a regulatory filing,…

In a regulatory filing, PDS Biotechnology disclosed that its CFO Seth Van Voorhees bought 17.6K shares of common stock on June 15th in a total transaction size of $150K.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$10.00 /

+0.655 (+7.01%)

PDSB PDS Biotechnology
$10.00 /

+0.655 (+7.01%)

06/09/21 Oppenheimer
PDS Biotechnology price target raised to $25 from $12 at Oppenheimer
06/09/21 Alliance Global Partners
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
06/08/21 Chardan
PDS Biotechnology price target raised to $15 from $11 at Chardan
06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
PDSB PDS Biotechnology
$10.00 /

+0.655 (+7.01%)

  • 15
    Jun
  • 11
    Aug
PDSB PDS Biotechnology
$10.00 /

+0.655 (+7.01%)

PDSB PDS Biotechnology
$10.00 /

+0.655 (+7.01%)

On The Fly
Fly Intel: After-Hours Movers » 19:01
06/17/21
06/17
19:01
06/17/21
19:01
SWBI

Smith & Wesson Brands

$19.93 /

-0.62 (-3.02%)

, ADBE

Adobe

$551.22 /

+8.16 (+1.50%)

, GERN

Geron

$1.40 /

-0.005 (-0.36%)

, CDXS

Codexis

$19.63 /

-0.23 (-1.16%)

, GEO

Geo Group

$7.23 /

-0.095 (-1.30%)

, FOXA

Fox Corp.

$37.16 /

-0.525 (-1.39%)

, ASAN

Asana

$53.55 /

+4.07 (+8.23%)

, X

U.S. Steel

$23.79 /

-2.01 (-7.79%)

, ATHA

Athira Pharma

$18.20 /

-0.35 (-1.89%)

, MGY

Magnolia Oil & Gas

$14.92 /

-0.89 (-5.63%)

, VERI

Veritone

$22.76 /

+0.95 (+4.36%)

Check out this evening's…

ShowHide Related Items >><<
X U.S. Steel
$23.79 /

-2.01 (-7.79%)

VERI Veritone
$22.76 /

+0.95 (+4.36%)

SWBI Smith & Wesson Brands
$19.93 /

-0.62 (-3.02%)

MGY Magnolia Oil & Gas
$14.92 /

-0.89 (-5.63%)

GERN Geron
$1.40 /

-0.005 (-0.36%)

GEO Geo Group
$7.23 /

-0.095 (-1.30%)

FOXA Fox Corp.
$37.16 /

-0.525 (-1.39%)

CDXS Codexis
$19.63 /

-0.23 (-1.16%)

ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

ASAN Asana
$53.55 /

+4.07 (+8.23%)

ADBE Adobe
$551.22 /

+8.16 (+1.50%)

SWBI Smith & Wesson Brands
$19.93 /

-0.62 (-3.02%)

03/05/21
Fly Intel: Top five analyst downgrades
03/05/21 Lake Street
Smith & Wesson Brands price target raised to $34 from $28 at Lake Street
03/05/21 Craig-Hallum
Smith & Wesson Brands downgraded to Hold from Buy at Craig-Hallum
03/05/21 Craig-Hallum
Smith & Wesson Brands downgraded to Hold from Buy at Craig-Hallum
ADBE Adobe
$551.22 /

+8.16 (+1.50%)

06/14/21 Jefferies
Adobe price target raised to $630 from $560 at Jefferies
05/24/21 Mizuho
Mizuho starts digital creativity and productivity 'titan' Adobe at Buy
05/24/21 Mizuho
Adobe initiated with a Buy at Mizuho
05/18/21 Jefferies
Adobe price target lowered to $560 from $610 at Jefferies
GERN Geron
$1.40 /

-0.005 (-0.36%)

02/18/21 B. Riley
Geron transferred with Buy rating at B. Riley Securities
10/14/20 B. Riley
Geron shares have 100% potential upside, says B. Riley Securities
08/26/20 H.C. Wainwright
Geron price target raised to $7 from $4 at H.C. Wainwright
08/03/20
Fly Intel: Top five analyst initiations
CDXS Codexis
$19.63 /

-0.23 (-1.16%)

04/12/21 Piper Sandler
Codexis initiated with an Overweight at Piper Sandler
03/01/21 Stifel
Codexis initiated with a Buy at Stifel
12/30/20 Benchmark
Codexis price target raised to $29 from $21 at Benchmark
07/15/20 Stephens
Codexis resumed with an Overweight at Stephens
GEO Geo Group
$7.23 /

-0.095 (-1.30%)

06/08/21 Wedbush
Wedbush sees Geo Group facing two major headwinds, initiates with Neutral
06/08/21 Wedbush
Geo Group initiated with a Neutral at Wedbush
06/29/20 Noble Capital
Geo Group initiated with an Outperform at Noble Capital
FOXA Fox Corp.
$37.16 /

-0.525 (-1.39%)

06/09/21 Wells Fargo
Fox upgraded to Overweight on sports betting opportunity at Wells Fargo
06/09/21 Wells Fargo
Fox Corp. upgraded to Overweight from Equal Weight at Wells Fargo
05/18/21 Morgan Stanley
Morgan Stanley says Amazon-MGM would be 'biggest signal yet' of streaming focus
05/18/21 Evercore ISI
Evercore says market likely views Discovery deal negatively for ViacomCBS, Fox
ASAN Asana
$53.55 /

+4.07 (+8.23%)

06/10/21 Baird
Asana price target raised to $50 from $40 at Baird
06/04/21 RBC Capital
Asana price target raised to $45 from $39 at RBC Capital
06/04/21 KeyBanc
Asana price target raised to $48 from $40 at KeyBanc
06/04/21 JMP Securities
Asana price target raised to $50 from $40 at JMP Securities
X U.S. Steel
$23.79 /

-2.01 (-7.79%)

06/16/21
Fly Intel: Top five analyst downgrades
06/16/21 JPMorgan
U.S. Steel assumed with Underweight from Neutral at JPMorgan
06/10/21 GLJ Research
GLJ ups U.S. Steel target, says valuation 'materially below reality'
06/04/21
Fly Intel: Top five analyst upgrades
ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

06/07/21 JMP Securities
Aducanumab accelerated approval positive for Athira, others, says JMP Securities
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
06/07/21 Jefferies
Athira Pharma could rise 25-50% in short-term after Biogen news, says Jefferies
10/13/20 Jefferies
Athira Pharma initiated with a Buy at Jefferies
MGY Magnolia Oil & Gas
$14.92 /

-0.89 (-5.63%)

05/27/21 Piper Sandler
Magnolia Oil & Gas upgraded to Overweight from Neutral at Piper Sandler
04/05/21 Seibert Williams
Magnolia Oil & Gas initiated with a Buy at Seibert Williams
03/11/21 Citi
Magnolia Oil & Gas reinstated with a Neutral at Citi
11/30/20 MKM Partners
Magnolia Oil & Gas downgraded to Neutral from Buy at MKM Partners
VERI Veritone
$22.76 /

+0.95 (+4.36%)

03/05/21 Northland
Veritone price target raised to $40 from $15 at Northland
03/05/21 Roth Capital
Veritone price target raised to $50 from $42 at Roth Capital
03/05/21 JMP Securities
Veritone price target raised to $45 from $21 at JMP Securities
02/23/21 Roth Capital
Veritone price target raised to $42 from $31 at Roth Capital
X U.S. Steel
$23.79 /

-2.01 (-7.79%)

VERI Veritone
$22.76 /

+0.95 (+4.36%)

SWBI Smith & Wesson Brands
$19.93 /

-0.62 (-3.02%)

MGY Magnolia Oil & Gas
$14.92 /

-0.89 (-5.63%)

GERN Geron
$1.40 /

-0.005 (-0.36%)

GEO Geo Group
$7.23 /

-0.095 (-1.30%)

FOXA Fox Corp.
$37.16 /

-0.525 (-1.39%)

CDXS Codexis
$19.63 /

-0.23 (-1.16%)

ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

ASAN Asana
$53.55 /

+4.07 (+8.23%)

ADBE Adobe
$551.22 /

+8.16 (+1.50%)

  • 18
    Jun
  • 03
    Mar
  • 03
    Feb
  • 21
    Jan
  • 03
    Dec
  • 03
    Dec
  • 18
    Sep
  • 18
    Jun
X U.S. Steel
$23.79 /

-2.01 (-7.79%)

VERI Veritone
$22.76 /

+0.95 (+4.36%)

SWBI Smith & Wesson Brands
$19.93 /

-0.62 (-3.02%)

GEO Geo Group
$7.23 /

-0.095 (-1.30%)

FOXA Fox Corp.
$37.16 /

-0.525 (-1.39%)

X U.S. Steel
$23.79 /

-2.01 (-7.79%)

VERI Veritone
$22.76 /

+0.95 (+4.36%)

SWBI Smith & Wesson Brands
$19.93 /

-0.62 (-3.02%)

MGY Magnolia Oil & Gas
$14.92 /

-0.89 (-5.63%)

GEO Geo Group
$7.23 /

-0.095 (-1.30%)

FOXA Fox Corp.
$37.16 /

-0.525 (-1.39%)

ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

ASAN Asana
$53.55 /

+4.07 (+8.23%)

ADBE Adobe
$551.22 /

+8.16 (+1.50%)

X U.S. Steel
$23.79 /

-2.01 (-7.79%)

SWBI Smith & Wesson Brands
$19.93 /

-0.62 (-3.02%)

GEO Geo Group
$7.23 /

-0.095 (-1.30%)

FOXA Fox Corp.
$37.16 /

-0.525 (-1.39%)

ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

ASAN Asana
$53.55 /

+4.07 (+8.23%)

ADBE Adobe
$551.22 /

+8.16 (+1.50%)

Periodicals
New York Times, The Athletic end merger talks, The Information reports » 18:45
06/17/21
06/17
18:45
06/17/21
18:45
NYT

New York Times

$40.33 /

+0.15 (+0.37%)

The New York Times and…

The New York Times and sports news site The Athletic have ended their merger talks, The Information's Sahil Patel reports, citing people familiar with the matter. The end of the deal came down to money as the people familiar with the matter said the two companies couldn't agree on a price. Reference Link

ShowHide Related Items >><<
NYT New York Times
$40.33 /

+0.15 (+0.37%)

NYT New York Times
$40.33 /

+0.15 (+0.37%)

05/06/21 JPMorgan
New York Times shares may be range-bound near term, says JPMorgan
03/18/21 Guggenheim
Guggenheim upgrades News Corp. to Buy, sees 'significant value' to be unlocked
11/09/20 Evercore ISI
New York Times upgraded to Outperform from In Line at Evercore ISI
10/27/20 JPMorgan
New York Times selloff brings attractive entry point, says JPMorgan
NYT New York Times
$40.33 /

+0.15 (+0.37%)

NYT New York Times
$40.33 /

+0.15 (+0.37%)

NYT New York Times
$40.33 /

+0.15 (+0.37%)

Periodicals
'PUBG Mobile' returns to India after nine month ban, TechCrunch says » 18:38
06/17/21
06/17
18:38
06/17/21
18:38
TCEHY

Tencent

$78.30 /

+1.72 (+2.25%)

, MSFT

Microsoft

$260.91 /

+3.44 (+1.34%)

Hit battle royale game…

Hit battle royale game "PUBG Mobile" is making a return to India after it was banned in the south Asian country more than nine months ago, TechCrunch's Manish Singh reports. The game was originally published by Tencent (TCEHY) but was relaunched as "Battlegrounds Mobile India" by Krafton, which filed for an IPO earlier this week, Singh says. The game, whose Xbox version is published by Microsoft (MSFT), was among 200+ apps banned in India last year amid security concerns, the author notes. Reference Link

ShowHide Related Items >><<
TCEHY Tencent
$78.30 /

+1.72 (+2.25%)

MSFT Microsoft
$260.91 /

+3.44 (+1.34%)

TCEHY Tencent
$78.30 /

+1.72 (+2.25%)

05/10/21 Macquarie
Agora price target lowered to $60 from $80 at Macquarie
03/22/21 Mizuho
Tencent price target raised to Rmb 710 from Rmb 600 at Mizuho
02/16/21 Barclays
Tencent price target raised to $115 from $89 at Barclays
01/26/21 KeyBanc
Tencent downgraded to Sector Weight on valuation at KeyBanc
MSFT Microsoft
$260.91 /

+3.44 (+1.34%)

06/16/21 William Blair
Microsoft gaming news opportunity not threat to Unity, says William Blair
06/15/21 Oppenheimer
Turtle Beach price target raised to $45 from $40 at Oppenheimer
06/07/21 Morgan Stanley
Microsoft valuation presents 'attractive entry point,' says Morgan Stanley
06/03/21 Tigress Financial
Microsoft shares going to $303 in 12 months, says Tigress Financial
MSFT Microsoft
$260.91 /

+3.44 (+1.34%)

TCEHY Tencent
$78.30 /

+1.72 (+2.25%)

MSFT Microsoft
$260.91 /

+3.44 (+1.34%)

TCEHY Tencent
$78.30 /

+1.72 (+2.25%)

MSFT Microsoft
$260.91 /

+3.44 (+1.34%)

MSFT Microsoft
$260.91 /

+3.44 (+1.34%)

Hot Stocks
Bristol-Myers, Eisai enter agreement to co-develop, commercialize MORAb-202 » 18:32
06/17/21
06/17
18:32
06/17/21
18:32
BMY

Bristol-Myers

$66.79 /

-0.13 (-0.19%)

, ESALY

Eisai

$103.62 /

+2.15 (+2.12%)

Eisai (ESALY) and…

Eisai (ESALY) and Bristol-Myers Squibb (BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate. MORAb-202 is Eisai's first ADC and combines Eisai's in house developed anti-folate receptor alpha antibody, and Eisai's anticancer agent eribulin, using an enzyme cleavable linker. It is a potential best-in-class FRalpha ADC with a favorable pharmacology profile and demonstrated single agent activity in patients with advanced solid tumors. Eisai is currently investigating MORAb-202 in FRalpha-positive solid tumors (inclusive of endometrial, ovarian, lung and breast cancers) in two studies: a Phase 1 clinical study in Japan and a Phase 1/2 clinical study in the United States. The companies are planning to move into the registrational stage of development for this asset as early as next year. Under the agreement, Eisai and Bristol Myers Squibb will jointly develop and commercialize MORAb-202 in the following collaboration territories: Japan; China; countries in the Asia-Pacific region; the United States; Canada; Europe, including the European Union and the United Kingdom; and Russia. Bristol Myers Squibb will be solely responsible for developing and commercializing the drug in regions outside of the collaboration territories. Eisai will remain responsible for the manufacturing and supply of MORAb-202 globally. Under the financial terms of the agreement, Bristol Myers Squibb will pay $650M U.S. dollars to Eisai including $200M U.S. dollars as payment toward Eisai research and development expenses. Eisai is also entitled to receive up to $2.45B U.S. dollars in potential future development, regulatory, and commercial milestones. The parties will share profits, research and development and commercialization costs in the collaboration territories and Bristol Myers Squibb will pay Eisai a royalty on sales outside of the collaboration territories. Eisai is expected to book sales of MORAb-202 in Japan, China, countries in the Asia-Pacific region, Europe and Russia. Bristol Myers Squibb is expected to book sales of MORAb-202 in the United States and Canada.

ShowHide Related Items >><<
ESALY Eisai
$103.62 /

+2.15 (+2.12%)

BMY Bristol-Myers
$66.79 /

-0.13 (-0.19%)

BMY Bristol-Myers
$66.79 /

-0.13 (-0.19%)

05/05/21 Wells Fargo
Wells sees 'limited impact' on Iovance's lifileucel from Keytruda/Yervoy data
04/30/21
Fly Intel: Top five analyst downgrades
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
ESALY Eisai
$103.62 /

+2.15 (+2.12%)

06/17/21 JPMorgan
Eisai upgraded to Overweight from Neutral at JPMorgan
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
BMY Bristol-Myers
$66.79 /

-0.13 (-0.19%)

BMY Bristol-Myers
$66.79 /

-0.13 (-0.19%)

ESALY Eisai
$103.62 /

+2.15 (+2.12%)

BMY Bristol-Myers
$66.79 /

-0.13 (-0.19%)

BMY Bristol-Myers
$66.79 /

-0.13 (-0.19%)

Hot Stocks
Azek CEO: We're very bullish about our future » 18:24
06/17/21
06/17
18:24
06/17/21
18:24
AZEK

Azek

$39.59 /

-0.795 (-1.97%)

In an interview on…

In an interview on CNBC's Mad Money, Jesse Singh said the value proposition Azek offers is a fantastic product with low maintenance. The vast amount of the company's portfolio is not subject to price swings of typical commodities. Azek uses hundreds of recycled materials with its products, he noted. "From an environmental standpoint, we're better because of recycled content." Singh said Azek has dramatically increased its marketing spend and expects the company to grow as consumer awareness of its products builds.

ShowHide Related Items >><<
AZEK Azek
$39.59 /

-0.795 (-1.97%)

AZEK Azek
$39.59 /

-0.795 (-1.97%)

05/14/21 Baird
Azek price weakness a buying opportunity, says Baird
05/05/21 JPMorgan
Azek initiated with a Neutral at JPMorgan
04/13/21 Wedbush
Wedbush starts Azek with Outperform, $52 price target
04/12/21 Wedbush
Azek initiated with an Outperform at Wedbush
AZEK Azek
$39.59 /

-0.795 (-1.97%)

  • 27
    May
  • 22
    Jan
  • 11
    Sep
AZEK Azek
$39.59 /

-0.795 (-1.97%)

Syndicate
Century Therapeutics 10.55M share IPO priced at $20.00 » 18:19
06/17/21
06/17
18:19
06/17/21
18:19
IPSC

Century Therapeutics

/

+

The deal priced at top…

The deal priced at top end of $18.00-$20.00 range. JPMorgan, BofA, SVB Leerink and Piper Sandler are acting as joint book running managers for the offering.

ShowHide Related Items >><<
  • 18
    Jun
Hot Stocks
Asana CEO buys 320K shares of common stock » 18:11
06/17/21
06/17
18:11
06/17/21
18:11
ASAN

Asana

$53.55 /

+4.07 (+8.23%)

In a regulatory filing,…

In a regulatory filing, Asana disclosed that its CEO Dustin Moskovitz bought 320K shares of common stock on June 15th in a total transaction size of $15.4M, boosting his stake by about 5%.

ShowHide Related Items >><<
ASAN Asana
$53.55 /

+4.07 (+8.23%)

ASAN Asana
$53.55 /

+4.07 (+8.23%)

06/10/21 Baird
Asana price target raised to $50 from $40 at Baird
06/04/21 RBC Capital
Asana price target raised to $45 from $39 at RBC Capital
06/04/21 KeyBanc
Asana price target raised to $48 from $40 at KeyBanc
06/04/21 JMP Securities
Asana price target raised to $50 from $40 at JMP Securities
ASAN Asana
$53.55 /

+4.07 (+8.23%)

ASAN Asana
$53.55 /

+4.07 (+8.23%)

ASAN Asana
$53.55 /

+4.07 (+8.23%)

Hot Stocks
Athira Pharma CEO Leen Kawas placed on temporary leave pending board review » 18:02
06/17/21
06/17
18:02
06/17/21
18:02
ATHA

Athira Pharma

$18.20 /

-0.35 (-1.89%)

Athira Pharm…

Athira Pharm "announced that Mark Litton, PhD, MBA, in his capacity as Chief Operating Officer, has assumed day-to-day leadership responsibilities for the company, effective immediately. This follows the Board's determination to place Leen Kawas, PhD, President and CEO of Athira, on temporary leave pending a review of actions stemming from doctoral research Dr. Kawas conducted while at Washington State University. Dr. Kawas will remain on the Board. The Board has formed an independent special committee to undertake this review. The Company does not intend to comment further on this matter until the review has concluded." Shares of Athira Pharma are down 39.7% afterhours at $11.00.

ShowHide Related Items >><<
ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

06/07/21 JMP Securities
Aducanumab accelerated approval positive for Athira, others, says JMP Securities
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
06/07/21 Jefferies
Athira Pharma could rise 25-50% in short-term after Biogen news, says Jefferies
10/13/20 Jefferies
Athira Pharma initiated with a Buy at Jefferies
ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

  • 21
    Jan
  • 18
    Sep
ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

ATHA Athira Pharma
$18.20 /

-0.35 (-1.89%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.